Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 2/20 | 0.57 |
| ▸ | DRD4 | P21917 | 11/20 | 0.56 |
| ▸ | DRD2 | P14416 | 9/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7778689 | 0.92 | DRD4 (0.55) | CCR3DRD4DRD2L3MBTL1NAMPT | |
| SCHEMBL7781191 | 0.87 | KDM4E (0.52) | CCR3DRD4DRD2SLC6A2SLC6A4 | |
| SCHEMBL7778614 | 0.82 | POLB (0.65) | L3MBTL1 | |
| SCHEMBL8989722 | 0.80 | DRD4 (0.55) | CCR3DRD4DRD2L3MBTL1CYP2C9 | |
| SCHEMBL7778722 | 0.80 | KDM1A (0.50) | SLC6A2SLC6A4 | |
| SCHEMBL8989753 | 0.80 | CCR3 (0.50) | CCR3DRD4DRD2NAMPT | |
| SCHEMBL7781120 | 0.80 | CCR3 (0.53) | CCR3DRD4DRD2NAMPTSLC6A2 | |
| SCHEMBL8989765 | 0.80 | SIGMAR1 (0.58) | DRD4DRD2NAMPTSLC6A2SLC6A4 | |
| SCHEMBL14430686 | 0.76 | DRD4 (0.70) | CCR3DRD4DRD2CYP2C9CYP2C19 | |
| SCHEMBL7781812 | 0.75 | POLB (0.62) | CCR3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1133293-A1 | USE OF N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM | BASF AKTIENGESELLSCHAFT (DE) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000030639-A1 | USE OF N-SUBSTITUTED AZABICYCLOALKANE DERIVATIVES FOR TREATING DISEASES OF THE CENTRAL NERVOUS SYSTEM | BASF AKTIENGESELLSCHAFT (DE) | 2000-06-02 | — | — | WO | disclosed |
| EP-0646110-B1 | N-SUBSTITUTED 3-AZABICYCLO[3.2.0]HEPTANE DERIVATIVES USEFUL AS NEUROLEPTIC AGENTS | BASF AG (DE) | 1996-10-23 | — | — | EP | disclosed |
| US-5521209-A | N-substituted azabicyclo[3.2.0]heptane derivatives as neuroleptics, the preparation and use thereof | BASF AKTIENGESELLSCHAFT (DE) | 1996-05-28 | — | — | US | disclosed |